InnoCare

InnoCare Pharma (HKEX: 09969; SSE: 688428) is a commercial-stage biopharmaceutical high-tech company, co-founded in 2015 by Dr. Jisong Cui, who has extensive experience in new drug research and development and corporate management, and Academician Yigong Shi, a world-renowned structural biologist. The company has resonated with the development of China's innovative drug industry, going through a magnificent golden decade side by side.

InnoCare has built a full industrial chain platform covering source innovation, clinical development, manufacturing, and commercialization, focusing on the development of first-in-class drugs for malignant tumors and autoimmune diseases. The company has independently developed a rich product pipeline, including three approved innovative drugs (Orelabrutinib, Tafasitamab, and Zurletrectinib), over ten innovative drugs in clinical stages, and multiple preclinical projects. The company has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.

InnoCare has maintained rapid yet steady development, achieving annual profitability in 2025 and continuing profitability in the first quarter of 2026, becoming one of the innovative drug enterprises that has crossed the breakeven point. Currently, the company has transitioned from being 'research and development-focused' to a new development stage of 'innovation-driven, sustainable commercialization, and global layout'.

In terms of research and development, the company has developed multiple innovative drugs, filling gaps in relevant therapeutic areas:

The novel BTK inhibitor Orelabrutinib (Yinuokai®) — the approved BTK inhibitor for treating marginal zone lymphoma, demonstrating efficacy in a Phase II clinical trial for systemic lupus erythematosus, and being one of the three BTK inhibitors in global development for major autoimmune diseases, currently in the new drug application and Phase III development stage.

The novel TRK inhibitor Zurletrectinib (Yinuoxin®) — an independently developed and approved TRK inhibitor.

The novel CD19 monoclonal antibody Tafasitamab (Mingnuokai®) — a CD19 monoclonal antibody approved for treating relapsed/refractory diffuse large B-cell lymphoma.

The novel BCL2 inhibitor Mesutoclax — a BCL2 inhibitor granted breakthrough therapy designation.

The novel TYK2 inhibitor Soficitinib (ICP-332) — a TYK2 inhibitor that has succeeded in a registrational Phase III clinical trial for atopic dermatitis.

The novel VAV1 molecular glue degrader ICP-538 — a VAV1 molecular glue degrader that has entered clinical trials.

The company also has over ten First-in-class and Best-in-class innovative drugs being accelerated in development in China and globally. In 2026, the company's multiple key pipelines are entering critical windows for data readouts and registrations, while continuously advancing the construction of its innovative pipeline, forming a systematic layout in areas such as small molecules, antibodies, and ADCs.

In terms of commercialization, the company has achieved sustained volume growth of core products, making its revenue structure more robust. The company has three approved products, with the core product Orelabrutinib receiving approvals for four indications, all included in the medical insurance catalog. The company is formally entering the era of a diversified product portfolio from a single product, committed to stronger commercial revenue.

In terms of globalization, the company has facilitated international cooperation on multiple products, including a cooperation exceeding $2 billion with multinational pharmaceutical company Zenas, setting a record for out-licensing of small-molecule drugs in China's autoimmune field. Currently, Orelabrutinib has been approved for marketing in Singapore and Australia, and the company has multiple projects in global clinical development stages, actively promoting international cooperation and out-licensing.

Standing at the starting point of the next decade, InnoCare will continue to be patient-need-oriented, persistently deepen innovation, drive commercial growth and global expansion, and accelerate its journey to become an internationalized innovative biopharmaceutical enterprise.

To date, InnoCare has over 1,400 employees, many of whom have overseas work experience and experience at Fortune Global 500 pharmaceutical companies, and include national, provincial, and municipal talent experts. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.